Status:
COMPLETED
Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Partnership for Clean Competition
Conditions:
Tendinopathy
Rheumatic Diseases
Eligibility:
All Genders
Brief Summary
Platelet-Rich Plasma (PRP) has been banned in competitive athletes because some people think it may enhance athletic performance. However, there is very little published research to support or undermi...
Detailed Description
To understand the short-term systemic effects of local PRP injections, we will measure the serum concentrations of six growth factors before and during the four days following PRP injection: human gro...
Eligibility Criteria
Inclusion
- Male and female patients 18-50 years old, receiving ultrasound-guided intratendinous or intramuscular PRP injections
Exclusion
- History of cancer, diabetes, hormone-replacement therapy, or abnormal nutritional habits.
- Contraindications for PRP therapy itself:
- preexisting coagulation defects including thrombocytopenia
- hypofibrinogenemia
- anticoagulation medications
- hypersensitivity to bovine products, which may be used for platelet activation.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01200875
Start Date
July 1 2010
End Date
May 1 2013
Last Update
August 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University Langone Orthopedic Hospital
New York, New York, United States, 10010